<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2985">
  <stage>Registered</stage>
  <submitdate>9/11/2010</submitdate>
  <approvaldate>9/11/2010</approvaldate>
  <nctid>NCT01239888</nctid>
  <trial_identification>
    <studytitle>Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression - A Pilot Study</studytitle>
    <scientifictitle>Phase IB Study of Efficacy and Safety of Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MAPRC 2010CK</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Depression</healthcondition>
    <healthcondition>Major Depressive Disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Oxytocin
Treatment: drugs - Oxytocin and Tibolone
Treatment: drugs - Placebo

Active Comparator: Oxytocin - 

Active Comparator: Oxytocin and Tibolone - 

Placebo Comparator: Placebo - 


Treatment: drugs: Oxytocin
20 IU of intranasal oxytocin twice per day for 8 weeks, and a placebo (oral) for the 8 week trial

Treatment: drugs: Oxytocin and Tibolone
20 IU of intranasal oxytocin twice per day for 8 weeks, and 2.5mg oral tibolone for the 8 week trial

Treatment: drugs: Placebo
20 IU of intranasal placebo twice per day for 8 weeks, and a placebo (oral) for the 8 week trial

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS)</outcome>
      <timepoint>Assessed at different time points: 1 week, 2 weeks, 4 weeks, 8 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in Hamilton Rating Scale for Depression (HAM-D)</outcome>
      <timepoint>Assessed at different time points: 1 week, 2 weeks, 4 weeks, 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in Beck Depression Inventory II (BDI-II)</outcome>
      <timepoint>Assessed at different time points: 1 week, 2 weeks, 4 weeks, 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in State Trait Anxiety Inventory (STAI)</outcome>
      <timepoint>Assessed at different time points: 1 week, 2 weeks, 4 weeks, 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse Symptom Check List</outcome>
      <timepoint>baseline, week 2, week 4, week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Perceived stress scale</outcome>
      <timepoint>baseline, week 2, week 4, week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pittsburgh sleep quality index</outcome>
      <timepoint>baseline, week 2, week 4, week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)</outcome>
      <timepoint>baseline, week 2, week 4, week 8</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Women

          -  18-45 years

          -  Current DSM-IV diagnosis of Major Depression

          -  Comorbid anxiety disorders secondary to depression will be included

          -  Past history of at least 2 failed treatment responses (including SSRIs) at the highest
             tolerated dose for at least 4-6 weeks

          -  A MADRS score &gt;20 at randomization

          -  Women on a stable dose of an SSRI (sertraline, citalopram, escitalopram, paroxetine,
             fluoxetine or fluvoxamine) for at least 4-6 weeks.

          -  A negative pregnancy test at screening

          -  A clinically acceptable Pap smear within the past 2 years

          -  Must be able to use intranasal spray and swallow tablets

        Patients may take up to 2 sleep medications permitted at a dose considered reasonable by
        the investigating team. Limited adjustments in sleep medication are acceptable. Patients
        will be asked to notify the researchers of any changes to their sleep medication.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Any previous history of adverse side-effects to escitalopram (or other SSRI)

          -  Use of oral contraceptives (or any hormonal method of contraception) for the duration
             of the study

          -  DSM-IV defined substance dependence, history of bipolar disorder, schizoaffective
             disorder or schizophrenia

          -  Significant unstable medical illness including epilepsy, diabetes or cardiac related,
             renal or liver disease, hormone dependent cancer or pregnancy

          -  A BMI&lt;18 or &gt; 34kg/m2

          -  Planning for pregnancy

          -  Renal disease, history of cerebrovascular disease, thrombo-embolic disorders,
             myocardial infarction or angina at any time before study entry or thrombo-phlebitis
             within the last 5 years, or any other major illness that has occurred within the last
             6 months.

          -  An undiagnosed genital bleeding

          -  Moderate to severe acne or hirsutism, have used antiandrogen therapy for acne or
             hirsutism in the preceding 5 years, have androgenic alopecia ( will exclude women with
             clinically meaningful androgen excess)

          -  Active malignancy, or treatment for malignancy in the preceding 6 months (excluding
             non-melanotic skin cancer)

          -  Alcohol consumption in excess of 3 standard drinks per day

          -  Lactose intolerance

          -  An abnormal thyroid stimulating hormone (TSH) value at screening confirmed by a Free
             T4 outside the normal laboratory range (patients with an abnormal TSH, normal Free T4
             and no clinical signs or symptoms of thyroid disease, with or without replacement
             treatment, may be admitted to the study).

          -  A history of allergic reactions to androgens (oral or patch)

          -  Chronic medications: aspirin and warfarin</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Monash Alfred Psychiatry Research Centre - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The Alfred</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Monash University</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether an oxytocin ad-on, or oxytocin and tibolone
      ad-on can induce a response to antidepressants in patients with treatment resistant
      depression.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01239888</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Charlotte Keating, PhD</name>
      <address>Monash University and the Alfred</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Charlotte Keating, PhD</name>
      <address />
      <phone>+61 3 9076 5180</phone>
      <fax />
      <email>charlotte.keating@monash.edu</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>